Uncategorized

United States Food & Drug Administration Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited announced that U.S. FDA has informed the company that following additional consideration the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease.

United States Food & Drug Administration Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease Read More »

Aptamer Sciences Inc. Files IND Application for Innovative Liver Cancer Treatment AST-201: A Promising Approach to Address Under Medical Needs

Aptamer Sciences Inc. announced the filing of an Investigational New Drug application for the phase 1 clinical trial of AST-201 with the Korean Ministry of Food and Drug Safety on March 12th, 2024.

Aptamer Sciences Inc. Files IND Application for Innovative Liver Cancer Treatment AST-201: A Promising Approach to Address Under Medical Needs Read More »

MiLaboratories Introduces Platforma Bio: A Revolutionary UI-First Computational Biology Platform powered by AI

MiLaboratories, a leader in developing best-in-class software for immunological data analysis, proudly announces the official launch of Platforma.bio . This groundbreaking computational biology platform, powered by AI large language models, is designed to significantly streamline, and simplify biological analysis, making it more accessible to researchers across various disciplines.

MiLaboratories Introduces Platforma Bio: A Revolutionary UI-First Computational Biology Platform powered by AI Read More »

Scroll to Top